HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Consumer’s Diverse Lineup Buoys Results As Pandemic Causes Slumps In Some Categories

Executive Summary

Prestige Consumer Healthcare says pandemic-caused sales slump for many of its OTC drug products was offset somewhat by strong sales of brands including Dentek, Monistat and Summer’s Eve, which were boosted by targeted advertising and promotions.

You may also be interested in...



Prestige Consumer Expects 4% Sales Dip For Its FY2021 As COVID-19 Clouds Economic Forecast

North American sales for the consumer health segment in the quarter reached $216.6m core products on women’s health, analgesics, oral care and ear and eye care categories, partially offset by declines in cough and cold products as well as gastrointestinal products.

Colgate Passes Again On Offering Earnings Guidance Due To Market ‘Complexity, Volatility’

Colgate won’t provide full-year 2020 guidance even as the company reports 5.5% organic growth in the second quarter. Its sales in North America grew 24% on pandemic-related purchasing and price increases.

Church & Dwight’s Consumer Health Product Sales Spared From Pandemic Plummet In Q2

C&D said sales of its brands including vitafusion, L’il Critters and PB8 supplements, Arm & Hammer, Aim and Close-Up toothpastes and Waterpick and Spinbrush power toothbrushes helped drive 8.8% growth to $386.4m for the personal and health care categories.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel